Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

Haematologica. 2020 Mar;105(3):e138-e140. doi: 10.3324/haematol.2019.232330. Epub 2019 Aug 29.

Authors

Sarolta Bojtine Kovacs¹, Jingting Luan¹, Sandra Maria Dold^{1

2}, Andreas Weis^{1

3}, Milena Pantic¹, Justus Duyster^{1

3}, Ralph Wäsch^{1

3}, Monika Engelhardt^{4

3}

Affiliations

¹ Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg.
² Faculty of Biology, University of Freiburg.
³ Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁴ Departments of Medicine 1, Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg monika.engelhardt@uniklinik-freiburg.de.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic
Dexamethasone / therapeutic use
Doxorubicin / therapeutic use
Humans
Male
Middle Aged
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Oligopeptides
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Oligopeptides
Sulfonamides
carfilzomib
Dexamethasone
Doxorubicin
venetoclax